2020
DOI: 10.1097/pr9.0000000000000877
|View full text |Cite
|
Sign up to set email alerts
|

Tapentadol treatment results in long-term pain relief in patients with chronic low back pain and associates with reduced segmental sensitization

Abstract: The endogenous pain system may be used as a biomarker in the pharmacological treatment of patients with CLBP, enabling an individualized, mechanism-based treatment approach.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(2 citation statements)
references
References 42 publications
0
2
0
Order By: Relevance
“…25 A site-specific impairment of OA was also shown in chronic low back pain, with an OA effect which was lower at the back than at the arm. 26 This may be explained by a somatotopic descending pain modulation in specific areas of the brain, such as the periaqueductal grey as a potential underlying mechanism. 27 To investigate potential influences and underlying mechanisms of OA, studies on healthy pain-free participants are often conducted.…”
Section: Discussionmentioning
confidence: 99%
“…25 A site-specific impairment of OA was also shown in chronic low back pain, with an OA effect which was lower at the back than at the arm. 26 This may be explained by a somatotopic descending pain modulation in specific areas of the brain, such as the periaqueductal grey as a potential underlying mechanism. 27 To investigate potential influences and underlying mechanisms of OA, studies on healthy pain-free participants are often conducted.…”
Section: Discussionmentioning
confidence: 99%
“…Somnolence and confusion may occur during treatment with tramadol, however, the risk of abuse is lower than other opioids [ 130 ]. Tapentadol, another µ-opioid agonist, has shown beneficial outcomes in the management of diabetic neuropathy and low back pain with a neuropathic component [ 174 , 175 , 176 , 177 ]. Other strong opioids such as oxycodone or morphine are recommended in the third-line treatment of neuropathic pain, but these agents are rarely utilized due to their high addiction potential [ 112 ].…”
Section: Treatment Strategies For Neuropathic Painmentioning
confidence: 99%